KR101455275B1 - 발기 부전의 치료를 위한 아세틸 엘 카르니틴과 프로피오닐엘 카르니틴 및 실데나필과의 병용된 용도 - Google Patents

발기 부전의 치료를 위한 아세틸 엘 카르니틴과 프로피오닐엘 카르니틴 및 실데나필과의 병용된 용도 Download PDF

Info

Publication number
KR101455275B1
KR101455275B1 KR1020077013019A KR20077013019A KR101455275B1 KR 101455275 B1 KR101455275 B1 KR 101455275B1 KR 1020077013019 A KR1020077013019 A KR 1020077013019A KR 20077013019 A KR20077013019 A KR 20077013019A KR 101455275 B1 KR101455275 B1 KR 101455275B1
Authority
KR
South Korea
Prior art keywords
treatment
carnitine
sildenafil
propionyl
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077013019A
Other languages
English (en)
Korean (ko)
Other versions
KR20070085961A (ko
Inventor
알레아르도 코베레치
지오르지오 카발리니
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20070085961A publication Critical patent/KR20070085961A/ko
Application granted granted Critical
Publication of KR101455275B1 publication Critical patent/KR101455275B1/ko
Assigned to 알파시그마 에스.피.에이. reassignment 알파시그마 에스.피.에이. 권리의 전부이전등록 Assignors: 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077013019A 2004-11-11 2005-10-19 발기 부전의 치료를 위한 아세틸 엘 카르니틴과 프로피오닐엘 카르니틴 및 실데나필과의 병용된 용도 Expired - Fee Related KR101455275B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000561A ITRM20040561A1 (it) 2004-11-11 2004-11-11 Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
ITRM2004A000561 2004-11-11
PCT/EP2005/011238 WO2006050794A1 (en) 2004-11-11 2005-10-19 Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction

Publications (2)

Publication Number Publication Date
KR20070085961A KR20070085961A (ko) 2007-08-27
KR101455275B1 true KR101455275B1 (ko) 2014-10-27

Family

ID=35501123

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077013019A Expired - Fee Related KR101455275B1 (ko) 2004-11-11 2005-10-19 발기 부전의 치료를 위한 아세틸 엘 카르니틴과 프로피오닐엘 카르니틴 및 실데나필과의 병용된 용도

Country Status (16)

Country Link
US (1) US8003652B2 (cg-RX-API-DMAC10.html)
EP (1) EP1811988B1 (cg-RX-API-DMAC10.html)
JP (1) JP5080263B2 (cg-RX-API-DMAC10.html)
KR (1) KR101455275B1 (cg-RX-API-DMAC10.html)
AT (1) ATE456950T1 (cg-RX-API-DMAC10.html)
CA (1) CA2585654C (cg-RX-API-DMAC10.html)
CY (1) CY1110239T1 (cg-RX-API-DMAC10.html)
DE (1) DE602005019251D1 (cg-RX-API-DMAC10.html)
DK (1) DK1811988T3 (cg-RX-API-DMAC10.html)
ES (1) ES2339265T3 (cg-RX-API-DMAC10.html)
IT (1) ITRM20040561A1 (cg-RX-API-DMAC10.html)
MX (1) MX2007005518A (cg-RX-API-DMAC10.html)
PL (1) PL1811988T3 (cg-RX-API-DMAC10.html)
PT (1) PT1811988E (cg-RX-API-DMAC10.html)
SI (1) SI1811988T1 (cg-RX-API-DMAC10.html)
WO (1) WO2006050794A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010222347A (ja) * 2009-02-24 2010-10-07 Daiichi Sankyo Healthcare Co Ltd Ｐｄｅ５阻害剤及びカルニチンを含有する医薬組成物
WO2012000634A1 (de) 2010-06-29 2012-01-05 Georg Bambach Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
WO2018070971A1 (ru) * 2016-10-10 2018-04-19 Товарыство З Обмэжэною Видповидальнистю Науково-Выробныча Фирма "Микрохим" Фармацевтическая композиция в форме оромукозного спрея для лечения эректильной дисфункции и легочной артериальной гипертензии

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047563A1 (en) * 2001-12-04 2003-06-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of alkanoyl l-carnitine for the treatment of erectile dysfunction

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69942200D1 (de) 1999-08-13 2010-05-12 Deutsches Krebsforsch Parvovirus NS1 Varianten
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
JP2001233770A (ja) * 2000-02-23 2001-08-28 Dountsuendorufaa Udo 勃起機能不全治療用の経口薬の組合わせ
ITRM20010621A1 (it) * 2001-10-18 2003-04-18 Aldo Fassi Sali metallici non igroscopici e idrosolubili di alcanoil l-carnitine, integratori dietetici che li contengono e kit dietetici, per contrast
ITRM20020620A1 (it) 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047563A1 (en) * 2001-12-04 2003-06-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of alkanoyl l-carnitine for the treatment of erectile dysfunction

Also Published As

Publication number Publication date
ES2339265T3 (es) 2010-05-18
PL1811988T3 (pl) 2010-07-30
PT1811988E (pt) 2010-04-08
KR20070085961A (ko) 2007-08-27
JP5080263B2 (ja) 2012-11-21
CA2585654A1 (en) 2006-05-18
CA2585654C (en) 2013-04-02
EP1811988B1 (en) 2010-02-03
WO2006050794A1 (en) 2006-05-18
JP2008531466A (ja) 2008-08-14
US8003652B2 (en) 2011-08-23
DK1811988T3 (da) 2010-05-17
SI1811988T1 (sl) 2010-10-29
EP1811988A1 (en) 2007-08-01
US20080090906A1 (en) 2008-04-17
ITRM20040561A1 (it) 2005-02-11
DE602005019251D1 (de) 2010-03-25
ATE456950T1 (de) 2010-02-15
MX2007005518A (es) 2007-05-18
CY1110239T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
US8158170B2 (en) Pharmaceutical composition comprising metadoxine and garlic oil for preventing and treating alcohol-induced fatty liver and steatohepatitis
JP2002505681A (ja) 健常人における気分障害を調節するための組成物
EP1737454A2 (en) Method of food intake management
US20140275183A1 (en) Agent for reducing side effects of kinase inhibitor
KR100567154B1 (ko) 트라마돌을 함유하는 약제학적 배합물
TWI331920B (en) Unit dosage form for relieving or treating constipation in human patients
Aminoff Basic & clinical pharmacology
ES2250749T3 (es) Uso de una composicion combinada que comprende propionil l-carnitina y otros farmacos para el tratamiento de la disfuncion erectil.
US8003652B2 (en) Use of acetyl L-carnitine in combination with propionyl L-carnitine and Sildenafil for the treatment of erectile dysfunction
EP1569635B1 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
KR100573010B1 (ko) 케탄제린 및 ｌ-카르니틴 또는 알카노일 ｌ-카르니틴을함유하는 ｃｒｐｓ 치료용 조성물
US7776913B2 (en) Carnitines for treating or preventing disorders caused by andropause
KR100420560B1 (ko) 포도당과 아미노산의 상승작용에 의한 관절염 및관절손상의 예방 및 치료제
EP4359077A1 (en) Dexmecamylamine and uses thereof
JP2022540664A (ja) 石灰化減少に用いる経口ピロリン酸二ナトリウム
WO2019125577A1 (en) Method of treatment of diabetic foot ulcers
MXPA06007693A (en) Method of food intake management

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

FPAY Annual fee payment

Payment date: 20171013

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20181011

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191022

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191022